Morphotek Inc. Announces Selection of a Therapeutic Monoclonal Antibody for Clinical Development under Terms of Collaboration with Human Genome Sciences, Inc.

EXTON, Pa.--(BUSINESS WIRE)--Morphotek®, Inc., a subsidiary of Eisai Inc., today announced that a monoclonal antibody has been selected for advancement to clinical development under the terms of its March 2009 collaboration agreement with Human Genome Sciences, Inc. (Nasdaq: HGSI). Under the agreement, the parties collaborate in the discovery, development and commercialization of antibodies that target certain antigens discovered by HGS. The collaborative work is focused on therapeutic monoclonal antibodies for the fields of immunology and oncology.